ATOS logo

ATOS
Atossa Therapeutics Inc

64,082
Mkt Cap
$100.78M
Volume
608.00
52W High
$1.36
52W Low
$0.5526
PE Ratio
-3.33
ATOS Fundamentals
Price
$0.7802
Prev Close
$0.752
Open
$0.7533
50D MA
$0.8971
Beta
1.23
Avg. Volume
1.35M
EPS (Annual)
-$0.2026
P/B
2.02
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation Atossa...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Atossa Genetics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Meets Estimates
Atossa Genetics (NASDAQ:ATOS - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07...
MarketBeat·11d ago
News Placeholder
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PR...
PR Newswire·12d ago
News Placeholder
Y Intercept Hong Kong Ltd Buys New Shares in Atossa Genetics Inc. $ATOS
Y Intercept Hong Kong Ltd acquired a new stake in shares of Atossa Genetics Inc. (NASDAQ:ATOS - Free Report) during the 2nd quarter, according to the company in its most recent filing with the...
MarketBeat·15d ago
News Placeholder
Atossa Genetics Inc. (NASDAQ:ATOS) Given Consensus Recommendation of "Hold" by Brokerages
Shares of Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report) have received an average recommendation of "Hold" from the five brokerages that are covering the company, Marketbeat Ratings reports...
MarketBeat·15d ago
News Placeholder
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium Atossa Therapeutics Announces...
PR Newswire·18d ago
News Placeholder
New Strong Sell Stocks for Oct. 22
ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
Zacks·1mo ago
News Placeholder
Atossa Therapeutics Highlights Progress in RECAST DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
Atossa Therapeutics Highlights Progress in RECAST DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine...
PR Newswire·1mo ago
News Placeholder
Atossa Therapeutics to Present at the Maxim Growth Summit 2025
Atossa Therapeutics to Present at the Maxim Growth Summit 2025 Atossa Therapeutics to Present at the Maxim Growth Summit 2025 PR Newswire SEATTLE, Oct. 15, 2025 Invites New Investors to Learn More...
PR Newswire·1mo ago
News Placeholder
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to...
PR Newswire·1mo ago

Latest ATOS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.